Search
Ribociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesFamitinib
go.drugbank.com/drugs/DB11741InvestigationalFamitinib has been used in trials studying the treatment of Colorectal Cancer, Renal Cell Cancer, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, and Metastatic Renal Cell Cancer, among others.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingOtenabant
go.drugbank.com/drugs/DB11745InvestigationalOtenabant has been investigated for the treatment of Obesity.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingCenicriviroc
go.drugbank.com/drugs/DB11758InvestigationalCenicriviroc has been used in trials studying the treatment of HIV-infection/AIDS, AIDS Dementia Complex, Nonalcoholic Steatohepatitis, Human Immunodeficiency Virus, and HIV-1-Associated Cognitive Motor
Categories: Heterocyclic Compounds, 1-RingPevonedistat
go.drugbank.com/drugs/DB11759InvestigationalPevonedistat has been used in trials studying the treatment of Lymphoma, Solid Tumors, Multiple Myeloma, Hodgkin Lymphoma, and Metastatic Melanoma, among others.
Categories: Heterocyclic Compounds, 1-RingImidapril
go.drugbank.com/drugs/DB11783InvestigationalImidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant.
Categories: Heterocyclic Compounds, 1-RingProducts: TANATRIL TABLETS 5 mg, ทานาทริล 5 มก. ชนิดเม็ดCapmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigationalCapmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades … [A199122] This co-occurrence has made c-Met a desirable target in the treatment of NSCLC.
Categories: MATE 2-K Inhibitors, MATE 1 InhibitorsNiraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigational[L43277] Niraparib is selective towards PARP-1 and PARP-2. … [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019.
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, MATE 2 Substrates with a Narrow Therapeutic IndexPrulifloxacin
go.drugbank.com/drugs/DB11892InvestigationalPrulifloxacin has been investigated for the treatment of Urinary Tract Infection.
Categories: 4-Quinolones, Heterocyclic Compounds, 1-RingPridopidine
go.drugbank.com/drugs/DB11947InvestigationalPridopidine has been used in trials studying the treatment of Huntington's Disease.
Categories: Heterocyclic Compounds, 1-Ring